Gilead Sciences Inc (GILD)

Current ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Total current assets	US$ in thousands	16,085,000	15,980,000	14,287,000	13,456,000	14,443,000	13,554,000	13,175,000	12,629,000	14,772,000	13,991,000	13,925,000	13,278,000	15,996,000	30,926,000	24,643,000	26,950,000	30,296,000	28,361,000	33,727,000	34,024,000
Total current liabilities	US$ in thousands	11,280,000	11,945,000	13,964,000	10,528,000	11,237,000	10,423,000	9,220,000	8,558,000	11,610,000	10,245,000	10,214,000	9,705,000	11,397,000	9,509,000	10,564,000	8,879,000	9,759,000	9,567,000	8,961,000	9,397,000
Current ratio		1.43	1.34	1.02	1.28	1.29	1.30	1.43	1.48	1.27	1.37	1.36	1.37	1.40	3.25	2.33	3.04	3.10	2.96	3.76	3.62

December 31, 2023 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $16,085,000K ÷ $11,280,000K
= 1.43

The current ratio of Gilead Sciences, Inc. has shown fluctuations over the past eight quarters, ranging from a low of 1.02 in Q2 2023 to a high of 1.48 in Q1 2022. The current ratio measures the company's ability to cover its short-term liabilities with its current assets. A ratio above 1 indicates that the company has sufficient current assets to cover its current liabilities.

In the recent quarters, the current ratio has generally been above 1, indicating that Gilead Sciences has been able to meet its short-term obligations. However, the significant decline in the current ratio in Q2 2023 to 1.02 may raise concerns about the company's liquidity position during that period. It is important to monitor the trend of the current ratio over time to assess the company's liquidity management and financial health.